Journals / JAREM / 2021 / Cilt: 11 - Sayı: 2

Relationship Between the Levels of 25-hydroxyvitamin D at Presentation and the Clinical, Laboratory and Follow-up Data of Children and Adolescents with Type-1 Diabetes Mellitus

Tip-1 Diabetes Mellitus Tanılı Çocuk ve Adölesan Olgularda Başvuru 25-hidroksivitamin D Düzeyleri ve Klinik, Laboratuvar, İzlem Verileri ile İlişkisi

Journal
JAREM
Pages
143–148
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We found that 25(OH)D levels affected clinical features at the time of diagnosis but not during follow-up.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to assess the relationship of 25-hydroxyvitamin D [25(OH)D] levels at presentation with the clinical, laboratory and followup data of children and adolescents with type-1 diabetes mellitus.
📊
Key Findings & Data:Methods: Patients who had available follow-up data and were diagnosed to have type-1 diabetes mellitus in our clinic between 2009 and 2015 were included.
💡
Conclusion & Impact:We found that 25(OH)D levels affected clinical features at the time of diagnosis but not during follow-up.
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: This study aimed to assess the relationship of 25-hydroxyvitamin D [25(OH)D] levels at presentation with the clinical, laboratory and followup data of children and adolescents with type-1 diabetes mellitus. Methods: Patients who had available follow-up data and were diagnosed to have type-1 diabetes mellitus in our clinic between 2009 and 2015 were included. Patient files were screened for data regarding presentation, history/family history and clinical, laboratory and follow-up data. Data were also assessed in the context of threshold values for sufficiency, insufficiency or deficiency of 25(OH)D. Results: The mean age was 8.62±14.19 years. Type-1 diabetes mellitus was diagnosed as diabetic ketoacidosis in 53.9% of the patients. The mean 25(OH)D level was 18.90±11.07 ng/mL at the time of diagnosis. The mean time to subcutaneous insulin therapy through the resolution of ketosis/ diabetic ketoacidosis in the group with vitamin D deficiency was significantly longer than vitamin D insufficient and sufficient groups (p=0.020). The mean 25(OH)D levels were lower in patients diagnosed with moderate and severe diabetic ketoacidosis (p=0.020). Insulin doses at discharge were significantly lower in patients with a mean 25(OH)D level of 10-20 ng/mL (p=0.039). The relationship of vitamin D groups with HbA1c and insulin doses in the follow-up period was not significant. Conclusion: This pilot study assessed the clinical, laboratory and follow-up data and the honeymoon status on month 2 (±1). We found that 25(OH)D levels affected clinical features at the time of diagnosis but not during follow-up.

Özet

Amaç: Çalışmamızda tip-1 diabetes mellituslu çocuk ve adölesan olgularımızın başvuru anındaki 25-hidroksivitamin D [25(OH)D] düzeyinin klinik, laboratuvar ve takip verileri ile ilişkisini değerlendirmeyi amaçladık. Yöntemler: Çalışmaya, kliniğimizde 2009 ve 2015 yılları arasında tip-1 diabetes mellitus tanısı almış takip verileri mevcut hastalar dahil edildi. Başvuru, özgeçmiş/aile öyküsü ve klinik, laboratuvar ve takip verileri ile ilgili sonuçlar için hasta dosyalarını taradık. Ek olarak, tüm veriler 25(OH)D yeterlilik/ yetersizlik/eksikliği için eşik değerler bağlamında değerlendirildi. Bulgular: Ortalama yaş 8,62±14,19 yıldı. Hastaların %53,9’unda tip-1 diabetes mellitus tanısı diyabetik ketoasidoz ile konmuştur. Tanı anında ortalama 25(OH)D düzeyi 18,90±11,07 ng/mL idi. D vitamini eksikliği olan grupta ketozis/diyabetik ketoasidozun rezolüsyonu ile subkütan insülin tedavisine kadar geçen ortalama süre anlamlı olarak daha uzundu (p=0,020). Orta ve şiddetli diyabetik ketoasidoz tanısı alan hastalarda ortalama 25(OH)D düzeyleri daha düşüktü (p=0,020). Ek olarak, taburcu edilirken ortalama 25(OH)D düzeyi 10-20 ng/mL olan hastalarda insülin dozları anlamlı olarak daha düşüktü (p=0,039). Takip döneminde D vitamini grupları ile HbA1c ve insülin dozları arasında anlamlı bir ilişki yoktu. Sonuç: Bu araştırma klinik, laboratuvar ve takip verilerinin yanı sıra özellikle 2. ayda (±1) balayı durumunu değerlendiren pilot bir çalışmadır. Çalışmamızda 25(OH)D düzeyinin tanı anında klinik özellikleri etkilediğini, ancak takip sırasında etkilemediğini bulduk.

🔖

Cite This Article

ERDEVE, Ş. S., ÇETİNKAYA, S., AYCAN, Z., YILMAZ, A. A., KARAMIK, G. (2022). Relationship Between the Levels of 25-hydroxyvitamin D at Presentation and the Clinical, Laboratory and Follow-up Data of Children and Adolescents with Type-1 Diabetes Mellitus. JAREM, Cilt: 11 - Sayı: 2, 143–148. https://ajindex.com/articles/558175

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994; 331: 1428-36
  2. Dahlquist GG, Patterson C, Soltesz G. Perinatal risk factors for childhood type 1 diabetes in Europe. The EURODIAB Substudy 2 Study Group. Diabetes Care 1999; 22: 1698-702
  3. Zella JB, DeLuca HF. Vitamin D and autoimmune diabetes. J Cell Biochem 2003; 88: 216-22
  4. Gregori S, Giarratana N, Smiroldo S, Uskovic M, Adorini L. A 1alpha 25 dihydroxyvitamin D (3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002; 51: 1367-74
  5. Dunger DB, Sperling MA, Acerini CL, Bohn DJ, Daneman D, Danne TPA, et al. ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. Arch Dis Child 2004; 89: 188-94
  6. Chase HP, Garg SK, Jelley DH. Diabetic ketoacidosis in children and the role of outpatient management. Pediatr Rev 1990; 11: 297-304
  7. Rosenbauer J, Dost A, Karges B, Hungele A, Stahl A, Bächle C, et al. Improved metabolic control in children and adolescents with type 1 diabetes. Diabetes Care 2012; 35: 80-6
  8. Abacı A, Böber E, Büyükgebiz A. Type 1 diabetes. Current Pediatrics 2007; 5: 1-10
  9. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-30
  10. Holick MF. Vitamin D: extraskeletal health. Rheum Dis Clin North Am 2012; 38:141-60
  11. Zerwekh JE. The measurement of vitamin D: analytical aspects. Ann Clin Biochem 2004; 41: 272-81
  12. Pozzilli P, Manfrini S, Crinò A, Picardi A, Leomanni C, Cherubini V, et al. Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes. Horm Metab Res 2005; 37: 680-3
  13. Littorin B, Blom P, Schölin A, Arnqvist HJ, Blohmé G, Bolinder J, et al. Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia 2006; 49: 2847-52
  14. Grant WB. Hypothesis--ultraviolet-B irradiance and vitamin D reduce the risk of viral infections and thus their sequelae, including autoimmune diseases and some cancers. Photochem Photobiol 2008; 84: 356-65
  15. Kraut JA, Gordon EM, Ransom JC, Horst R, Slatopolsky E, Coburn JW et al. Effect of chronic metabolic acidosis on vitami